Research Library — Eli Lilly — Page 2 | Reta Compare
49 research articles in Eli Lilly. Page 2 of 2.
Articles
- Eli Lilly Financial Impact of Compounded GLP-1 Market
- Media Coverage of the Lilly-Telehealth Battles
- Eli Lilly Press Releases on Compounded Peptide Safety
- State Attorney General Coordination with Lilly Cases
- The Public Interest Defense in Compounded Tirzepatide Cases
- First Amendment Defenses in Lilly Compounded Peptide Litigation
- Preemption Arguments in Compounded GLP-1 Cases
- Eli Lilly Amicus Briefs on Compounded Drug Policy
- Eli Lilly's 10-K Disclosures on Compounded Tirzepatide Risk
- Eli Lilly Investor Day Comments on Compounded Peptides
- Eli Lilly Earnings Calls and Compounded Market Discussion
- Ex Parte Seizure Orders Against Compounded GLP-1 Counterfeiters
- Customs and Border Protection Coordination with Lilly
- The Lilly-Telehealth Dispute in State Pharmacy Board Proceedings
- Lilly Advertising Campaign Against Compounded Tirzepatide
- The Lilly 'Safety Doesn't Discount' Campaign
- Case Consolidation in Lilly Compounded Tirzepatide MDL Discussions
- Lilly's Subpoenas to API Suppliers in Compounded Cases
- How Lilly Coordinates with Novo Nordisk on Shared Issues
- Lilly's Pursuit of Import Records for Foreign API
- Lilly's Discovery Requests for Prescription Records
- Regulatory-Litigation Interaction: Lilly Cases After FDA Warning Letters
- Lilly's Policy Lobbying on Compounded Peptide Legislation
- The Compounding Industry's Response to Lilly Enforcement